论文部分内容阅读
目的探讨IL-10、IL-12在结直肠癌肝转移中作用。方法分别收集自2008年1月到2010年6月健康成年人、结直肠癌术前、术后和术后肝转移患者外周血,采用ELISA法测定外周血清IL-10、IL-12水平,采用FACS Calibur3.0流式细胞仪测定T淋巴细胞及其亚群比例,进行各组结果统计学分析。结果结直肠癌术后肝转移患者外周血清IL-10水平显著高于健康成年人、结直肠癌术后患者(P<0.05),结直肠癌术后患者外周血清IL-10水平显著低于术前患者(P<0.05);结直肠癌术前、术后和术后肝转移患者外周血清IL-12水平显著低于健康成年人,结直肠癌术前、术后患者之间以及术后和术后肝转移患者之间外周血清IL-12水平存在统计学差异(P<0.05);结直肠癌术后肝转移患者外周血T淋巴细胞总数及Th细胞比例数显著低于健康成年人(P<0.05),Ts细胞比例数显著高于健康成年人(P<0.05)。NK细胞在结直肠癌术后肝转移患者显著低于健康成年人(P<0.05)。结论不同临床时期结直肠癌患者存在细胞免疫或体液免疫严重障碍,纠正机体细胞因子和免疫状态紊乱,不仅能够改善机体免疫功能,可能有助于控制结直肠癌的发生、发展。
Objective To investigate the role of IL-10 and IL-12 in liver metastasis of colorectal cancer. Methods Peripheral blood samples from healthy adults, preoperative, postoperative and postoperative liver metastases from January 2008 to June 2010 were collected. Serum levels of IL-10 and IL-12 were measured by ELISA. FACS Calibur3.0 flow cytometry T lymphocytes and its proportion of subgroups, statistical analysis of the results of each group. Results The serum level of IL-10 in patients with postoperative liver metastasis of colorectal cancer was significantly higher than that in healthy adults and patients with postoperative colorectal cancer (P <0.05). The level of IL-10 in peripheral blood was significantly lower in patients with colorectal cancer after operation (P <0.05). The serum levels of IL-12 in peripheral blood of patients with colorectal cancer preoperative, postoperative and postoperative liver metastasis were significantly lower than those of healthy adults, and the preoperative and postoperative patients with colorectal cancer and postoperative The level of IL-12 in peripheral blood of patients with postoperative liver metastasis was significantly different (P <0.05). The number of T lymphocytes and the proportion of Th cells in peripheral blood of postoperative patients with liver metastasis were significantly lower than those in healthy adults (P <0.05), the proportion of Ts cells was significantly higher than healthy adults (P <0.05). NK cells in patients with postoperative liver metastasis of colorectal cancer was significantly lower than healthy adults (P <0.05). Conclusions Patients with colorectal cancer in different clinical stages may have severe cellular or humoral immune disorders. Correcting the abnormalities of cytokines and immune status in colorectal cancer patients may not only improve the immune function but also help control the occurrence and development of colorectal cancer.